Drug-Resistant Gonorrhea Spreading Inside Europe, Health Officials Warn

Until recently, a European doctor who saw gonorrhea shrug off antibiotics could usually guess the patient’s recent itinerary. Resistant strains showed up in people who had been to South-East Asia, or who had slept with someone who had. Those cases were rare, scattered, and traceable. European health authorities now report that the pattern has broken: patients with no travel history at all are testing positive, and the bacteria are passing from person to person on the continent itself.

On Thursday, the European Centre for Disease Prevention and Control (ECDC) published a risk assessment on an upsurge in gonorrhea caused by strains that resist ceftriaxone, the antibiotic that anchors first-line treatment across Europe and the United States. Cases described in the assessment come from 12 European countries. What changed during 2025 and the first half of 2026 was not simply volume. Clusters appeared. Infections turned up in people who had not left the country. Agency analysts concluded that domestic transmission is underway, and that importation is no longer the only engine driving the spread.

Sweden found seven of its 13 resistant infections from 2025 and 2026 were acquired at home. Germany’s two cases in 2026 reported no travel. Norway logged two cases in April 2026 that were directly linked to each other. France and Britain each turned up defined clusters, meaning the infection was handed onward after it landed. Agency authors wrote that despite every reported case eventually being cured, “the increasing detections, evidence of domestic transmission, and narrowing treatment options indicate a risk of further escalation if control measures are not implemented and maintained.”

Drug-Resistant Gonorrhea Still Arrives by Plane, and Now Spreads at Home

Gonorrhea is common and getting more so. Roughly 82 million new infections occur worldwide each year among people aged 15 to 49. Across the European Union and European Economic Area, 106,331 confirmed cases were reported in 2024, about 26.9 per 100,000 people and the highest count since regional surveillance began in 2009. Notification rates have climbed 303% since 2015, though part of that rise probably reflects wider testing and better reporting rather than transmission alone.

Resistant infections make up a tiny fraction of that total, which is exactly why the recent shift registered. Importation still matters: travel to Cambodia, Indonesia, Thailand, and Vietnam appears repeatedly in the case histories, and repeated introductions keep seeding genetically varied strains into European populations. France has additionally traced infections acquired inside Europe, in Germany, Spain, and Britain, plus Tunisia. Once those strains arrive, some of them stay and circulate.

Untreated gonorrhea is not a minor nuisance. It can cause pelvic inflammatory disease, infertility, ectopic pregnancy, chronic pelvic pain, and inflammation of the testicles, and in rare cases it spreads through the bloodstream.

Case Counts Bending Upward in Four Countries

Sweden logged between zero and three ceftriaxone-resistant cases per year from 2020 through 2024. In 2025 it found nine, and four more arrived in the first half of 2026.

France reported two cases in 2022 and four in 2023. Since January 2025 it has identified at least 17 multidrug-resistant or extensively drug-resistant infections, spread across three separate clusters in different parts of the country. Most involved heterosexual patients, and five were acquired domestically.

Germany counted seven resistant cases in 2025, five of them tied to travel in South-East Asia and two to transmission inside Germany. Britain has the steepest slope of all: 13 cases in 2024, 29 in 2025, and 17 already by June of 2026. In April and May, six cases surfaced inside a single sexual network with no recent international travel reported.

Elsewhere the picture stays sporadic. Denmark reported three travel-linked cases across 2025 and 2026 with no onward spread. Austria, Ireland, and the Netherlands logged single cases. Spain and Croatia each reported one case in 2026 with no confirmed travel history, which may mean the infection was picked up locally.

When the Standard Shot Stops Working

Doctors treating these patients have been reaching for bigger hammers. Standard care in most reported cases was ceftriaxone alone, at 500 milligrams to 1 gram. Croatia and Germany pushed doses as high as 2 grams intravenously, sometimes repeated or stretched across days. Austria, Germany, Norway, and Spain paired ceftriaxone with azithromycin.

According to the assessment, “six treatment failures have been reported to date, all involving extra-genital infections (five pharyngeal and one rectal).” All six were in Britain. Four cleared after a second round of ceftriaxone plus azithromycin. Two required ertapenem, an intravenous drug normally reserved for serious hospital infections, delivered by drip rather than by a quick jab at a sexual health clinic.

Both details in that sentence matter. ECDC notes that pharyngeal infections may be harder to eradicate and carry a higher risk of treatment failure, and recommends a culture-based test after treatment to confirm the infection has actually cleared, especially in throat cases. Gonorrhea can also be silent: the agency advises public messaging to stress that infections may produce no symptoms at all, which means someone can carry the bacteria, feel fine, never get tested, and pass it along.

Laboratory work points to a specific genetic culprit: mosaic versions of a gene called penA, which alters the bacterial protein that ceftriaxone is built to attack. Some strains also carry high-level resistance to azithromycin, the usual backup partner drug. Genetic fingerprinting found both wide diversity, consistent with many separate introductions from abroad, and evidence of a few specific lineages spreading under their own steam within Europe.

Who Is Catching Drug-resistant Gonorrhea in Europe

Patients in the reported cases are mostly adults between 20 and 50, and 60% to 80% are male. Most had symptoms of urethritis, the burning and discharge that sends people to a clinic in the first place. Transmission, where reported, was predominantly heterosexual, frequently connected to sexual networks with high partner turnover, including sex work.

That pattern runs against the demographic shape of European gonorrhea overall. In 2024, transmission among men who have sex with men accounted for 62% of all reported cases across the region. Resistant infections are moving through different channels, and the channels appear to be widening. In 2026, per the assessment, “the first cases among bisexual men and women were reported in the UK, suggesting spread beyond previously affected sexual networks.”

Scale is the counterweight to all of it. Resistant cases remain sporadic across the region, and ECDC states there is no evidence of sustained community transmission at this stage. Agency analysts rate the overall risk to sexually active Europeans who are not engaging in higher-risk behavior as low. For people with multiple or frequently changing partners, or condomless sex with new or casual partners, the rating rises to low-to-moderate. For someone who travels to a region where resistant strains circulate widely and has condomless sex there, the risk is rated moderate.

Gonorrhea has burned through the medicine cabinet before. Penicillin, tetracycline, and ciprofloxacin all worked once and now largely do not; ciprofloxacin resistance across Europe sat at 63.7% in 2024. Ceftriaxone is the backstop, and globally, resistance to it climbed from 0.8% to 5% between 2022 and 2024, while resistance to a related oral drug, cefixime, went from 1.7% to 11%. Agency authors called that trend “alarming given ceftriaxone’s central role in treatment guidelines and the limited availability of effective alternative therapies.” Two replacements, zoliflodacin and gepotidacin, have cleared late-stage trials, and ECDC advises countries to arrange access routes now instead of after the current regimens quit.

Detection is the weak link in all of it. Many gonorrhea diagnoses rely on genetic tests that identify the bacteria without ever growing it in a dish, and without a culture there is no way to learn which drugs it defeats. Only 24 of 30 EU countries took part in the regional resistance surveillance program in 2024. Resistant cases nobody cultures are resistant cases nobody counts, so the tally in this assessment is a floor rather than a ceiling. Whatever is circulating in Europe right now, the map is drawn from the cases that happened to be looked at closely.

Disclaimer: This article summarizes a public health risk assessment, not a clinical trial or peer-reviewed study. Risk assessments compile case reports voluntarily submitted by national authorities, and ECDC states that under-detection and under-reporting cannot be excluded, that surveillance capacity differs sharply between countries, and that key details such as travel history and site of infection are inconsistently reported. Case counts therefore describe what surveillance systems caught, not the true number of infections. Risk ratings apply to populations, not individuals, and nothing here should be read as personal medical advice. Anyone with symptoms of a sexually transmitted infection, or a possible exposure, should seek testing from a clinician.